Hoitt Jason
Chief Patient Officer
Hoitt Jason has filed 2 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 19, 2026.
On the most recent filing, Hoitt Jason is listed as Chief Patient Officer at Stoke Therapeutics, Inc. Inside the rolling window, Hoitt Jason reported no open-market purchases and 2 open-market sales totaling $119K in STOK. The largest disclosed transaction in the window is a sale of 1,931 STOK shares on Mar 18, 2026, worth $61K.
Companies traded
Other insiders at STOK
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$119K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hoitt Jason made?
Hoitt Jason has filed 2 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does Hoitt Jason trade?
Hoitt Jason has filed SEC Form 4 disclosures for 1 company, including STOK.
When was Hoitt Jason's most recent SEC Form 4 filing?
Hoitt Jason's most recent SEC Form 4 filing on Tracefour is dated Mar 19, 2026.
What is Hoitt Jason's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Hoitt Jason is listed as Chief Patient Officer.
What is Hoitt Jason's total buy and sell value in the current window?
Inside the rolling retention window, Hoitt Jason bought $0 and sold $119K based on SEC Form 4 filings.
What was Hoitt Jason's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,931 STOK shares on 2026-03-18, worth $61K, per SEC Form 4 filings.